0000899243-16-020933.txt : 20160525 0000899243-16-020933.hdr.sgml : 20160525 20160525181509 ACCESSION NUMBER: 0000899243-16-020933 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160523 FILED AS OF DATE: 20160525 DATE AS OF CHANGE: 20160525 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Emergent BioSolutions Inc. CENTRAL INDEX KEY: 0001367644 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 141902018 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 400 PROFESSIONAL DR, SUITE 400 CITY: GAITHERSBURG STATE: MD ZIP: 20879 BUSINESS PHONE: 240-631-3200 MAIL ADDRESS: STREET 1: 400 PROFESSIONAL DR, SUITE 400 CITY: GAITHERSBURG STATE: MD ZIP: 20879 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: El-Hibri Fuad CENTRAL INDEX KEY: 0001380185 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33137 FILM NUMBER: 161675741 MAIL ADDRESS: STREET 1: 2273 RESEARCH BLVD, SUITE 400 CITY: ROCKVILLE STATE: MD ZIP: 20850 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2016-05-23 0 0001367644 Emergent BioSolutions Inc. EBS 0001380185 El-Hibri Fuad 400 PROFESSIONAL DRIVE, SUITE 400 GAITHERSBURG MD 20879 1 1 1 0 Chairman Common Stock 2016-05-23 4 M 0 20000 15.91 A 1719073 D Common Stock 2016-05-23 4 S 0 20000 42.76 D 1699073 D Common Stock 2016-05-23 4 S 0 25000 42.50 D 1674073 D Common Stock 2016-05-24 4 M 0 20000 15.91 A 1694073 D Common Stock 2016-05-24 4 S 0 20000 42.26 D 1674073 D Common Stock 2016-05-25 4 M 0 20000 15.91 A 1694073 D Common Stock 2016-05-25 4 S 0 20000 42.57 D 1674073 D Common Stock 2350331 I By Intervac, L.L.C. Common Stock 1524155 I By Biovac, L.L.C. Employee Stock Option (right to buy) 15.91 2016-05-23 4 M 0 20000 0.00 D 2017-03-08 Common Stock 20000 64594 D Employee Stock Option (right to buy) 15.91 2016-05-24 4 M 0 20000 0.00 D 2017-03-08 Common Stock 20000 44594 D Employee Stock Option (right to buy) 15.91 2016-05-25 4 M 0 20000 0.00 D 2017-03-08 Common Stock 20000 24594 D The transactions reported herein were effectuated by the Reporting Person pursuant to two separate trading plans adopted on February 29, 2016, each of which are intended to comply with Rule 10b5-1(c) under the Exchange Act. The selling price of $42.76 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $42.29 to $42.85, inclusive. The Reporting Person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. The selling price of $42.26 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $41.58 to $42.49, inclusive. The Reporting Person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. The selling price of $42.57 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $42.15 to $42.93, inclusive. The Reporting Person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Mr. El-Hibri's holdings through Intervac, L.L.C. include 1,638,403 shares of Common Stock held by Mr. El-Hibri and his wife, as tenants by the entirety, through their 37.7% equity interest in Intervac, L.L.C.; 127,721 shares held by Mr. El-Hibri's wife; and 584,207 shares held by trusts indirectly controlled by Mr. El-Hibri or his wife. Mr. El-Hibri disclaims beneficial ownership, for purposes of Section 16 of the Exchange Act or otherwise, of those shares held solely by his wife and those shares held by the trusts. Mr. El-Hibri holds individually and with his wife, as tenants by the entirety, an aggregate 89.2% equity interest in Biovac, L.L.C. Biovac, L.L.C. is the direct owner of 1,524,155 shares of Common Stock. Mr. El-Hibri disclaims beneficial ownership of the shares of Common Stock directly owned by Biovac, L.L.C. for purposes of Section 16, except to the extent of his pecuniary interest in 1,359,546 shares. The options vested in three equal installments on March 9, 2011, March 9, 2012 and March 9, 2013. /s/ Carl A. Valenstein, attorney-in-fact 2016-05-25